Zevenbergen Capital Investments LLC Invests $14.66 Million in Caris Life Sciences, Inc. $CAI

Zevenbergen Capital Investments LLC acquired a new position in Caris Life Sciences, Inc. (NASDAQ:CAI) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 543,185 shares of the company’s stock, valued at approximately $14,655,000.

Separately, Olistico Wealth LLC bought a new stake in Caris Life Sciences in the 4th quarter valued at $31,000.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CAI shares. Robert W. Baird raised their price target on shares of Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. BTIG Research decreased their target price on Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Canaccord Genuity Group reduced their price objective on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating for the company in a research report on Friday, March 13th. Wall Street Zen upgraded Caris Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $31.50.

Caris Life Sciences Price Performance

Caris Life Sciences stock opened at $16.85 on Tuesday. The stock’s 50 day moving average is $20.73. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The company has a market cap of $4.76 billion and a P/E ratio of -93.61. Caris Life Sciences, Inc. has a one year low of $16.28 and a one year high of $42.50.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. During the same quarter last year, the company earned ($1.73) earnings per share. The business’s revenue was up 125.4% on a year-over-year basis.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.